Acrivon Therapeutics (NASDAQ:ACRV) Now Covered by KeyCorp

Stock analysts at KeyCorp began coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a report released on Friday,Briefing.com Automated Import reports. The firm set an “overweight” rating on the stock.

A number of other analysts have also commented on the stock. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Acrivon Therapeutics in a research report on Thursday, November 14th. BMO Capital Markets reduced their price objective on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Acrivon Therapeutics presently has an average rating of “Buy” and an average target price of $23.67.

Acrivon Therapeutics Stock Performance

Shares of Acrivon Therapeutics stock opened at $5.79 on Friday. Acrivon Therapeutics has a 52-week low of $3.19 and a 52-week high of $11.90. The business’s 50 day simple moving average is $6.35 and its 200 day simple moving average is $7.35. The firm has a market cap of $180.30 million, a PE ratio of -2.14 and a beta of 0.77.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ACRV. State Street Corp grew its holdings in Acrivon Therapeutics by 26.4% during the third quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after purchasing an additional 47,233 shares during the period. Exome Asset Management LLC acquired a new stake in shares of Acrivon Therapeutics in the third quarter valued at approximately $817,000. JPMorgan Chase & Co. boosted its stake in shares of Acrivon Therapeutics by 548.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock worth $238,000 after acquiring an additional 28,748 shares during the period. Barclays PLC boosted its stake in shares of Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after acquiring an additional 11,273 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in Acrivon Therapeutics in the 2nd quarter valued at $58,000. 71.62% of the stock is currently owned by institutional investors and hedge funds.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.